ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1196

Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies

Zubeyir Salis1 and Amanda Sainsbury2, 1The University of New South Wales, Kensington, Australia, 2The University of Western Australia, Crawley, Australia

Meeting: ACR Convergence 2023

Keywords: Nonsteroidal antiinflammatory drugs (NSAIDs), Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1183–1199) Osteoarthritis – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are commonly prescribed for short-term management of symptoms of knee osteoarthritis (KOA), but they are often used long-term, and the long-term effects are unclear. Therefore, we aimed to investigate the association of long-term use of NSAIDs with KOA symptoms and structural changes.

Methods: We performed individual patient data meta-analysis of three independent cohort studies: Osteoarthritis Initiative (OAI); Multicenter Osteoarthritis (MOST); and Cohort Hip and Cohort Knee (CHECK). The participants had or were at risk of developing KOA. A participant was classified as long-term user of NSAIDs if they were using them at baseline and during all follow-up visits. The follow-up visits occurred annually over 4 years in OAI, over 5 years in CHECK, and every 2.5 years over 5 years in MOST. A participant was classified as a non-user of NSAIDs if they did not use it at baseline and at any follow-up visits. There were 435 participants (with 870 knees) identified as long-term users of NSAIDs, and 3,762 participants (with 7,524 knees) identified as non-users. Outcomes included worsening pain, disability, and stiffness, assessed by the Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores, structural changes assessed by Kellgren/Lawrence (K/L) grades, and incidence of total knee replacement. Generalized estimating equations were used to assess the association of long-term use of NSAIDs with the change in outcomes between baseline and the 4-to-5-year follow-up, accounting for the clustering of left and right knees within each participant. The analyses were adjusted for sex; race; baseline values of age; body mass index (BMI); smoking status; comorbidity score; walking for leisure or activity; the pain, disability, and stiffness scores on WOMAC; the severity of osteoarthritis as assessed by K/L grades; and study cohort (OAI, MOST, and CHECK).

Results: Compared to non-users, long-term users of NSAIDs had significantly increased odds of worsening pain, disability, and stiffness that was of a clinically meaningful degree. The odds ratios (OR) were 2.04 (95% confidence intervals [CI]: 1.66 to 2.49) for pain, 2.21 (95% CI: 1.74 to 2.80) for disability, and 1.58 (95% CI: 1.29 to 1.93) for stiffness. For structural changes, compared to non-users, long-term users of NSAIDs had significantly increased odds of worsening in both severity of structural changes of KOA (OR: 1.43; 95% CI: 1.15 to 1.77) and incidence of total knee replacement (OR: 3.13; 95% CI: 2.08 to 4.70).

Conclusion: Long-term use of NSAIDs may have detrimental effects on KOA, including worsening symptoms and structural changes. Although NSAIDs are useful for short-term management of KOA symptoms, our findings highlight potential adverse effects of long-term use. Therefore, healthcare providers should weigh the benefits and risks of long-term NSAID use in patients with KOA and consider alternative strategies to improve patient outcomes in the long term.


Disclosures: Z. Salis: Zuman International Pty Ltd, 8, 9; A. Sainsbury: Zuman International Pty Ltd, 6, 8, 9.

To cite this abstract in AMA style:

Salis Z, Sainsbury A. Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/association-of-long-term-use-of-non-steroidal-anti-inflammatory-drugs-nsaids-with-worsening-symptoms-and-structural-changes-of-knee-osteoarthritis-an-individual-patient-data-meta-analysis-of-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-long-term-use-of-non-steroidal-anti-inflammatory-drugs-nsaids-with-worsening-symptoms-and-structural-changes-of-knee-osteoarthritis-an-individual-patient-data-meta-analysis-of-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology